secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rezolute, Inc. (RZLT)
CIK:        0001509261
Form:       8-K
Filed at:   2026-09-24T20:16:39+00:00
Accession:  0001104659-26-110412
Event type: earnings
Sentiment:  negative
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rezolute FY26 net loss $77.6M; cash $107.8M; upLIFT positive, sunRIZE under FDA review
--------------------------------------------------------------------------------

- Cash and investments $107.8M at Jun 30, 2026, down from $167.9M at Jun 30, 2025.
- FY2026 net loss $77.6M vs $74.4M FY2025; Q4 net loss $20.5M vs $24.4M year ago.
- R&D FY26 $53.8M (down from $61.5M); G&A FY26 $29.2M (up from $18.4M).
- upLIFT Phase 3: 7 of 8 enrolled participants met primary endpoint responder criterion; topline results expected before end of 2026.
- sunRIZE Phase 3 congenital HI missed primary endpoint; data remains under FDA review; OLE ongoing with improved glycemic control.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/0001104659-26-110412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-110412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer